Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22752296 | 0.85 | PIK3CA (0.35) | ALDH1A1NPSR1CNR2SMN1; SMN2MEN1 | |
| SCHEMBL17996185 | 0.82 | ALDH1A1 (0.38) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL91419 | 0.80 | MAPT (0.37) | ALDH1A1MEN1KMT2ATSHRNPC1 | |
| SCHEMBL19592858 | 0.77 | PIK3CA (0.42) | MAPT | |
| SCHEMBL25454479 | 0.73 | ALOX5 (0.43) | ALDH1A1NPSR1CNR2SMN1; SMN2MEN1 | |
| SCHEMBL20288216 | 0.72 | NPC1 (0.40) | ALDH1A1NPSR1CNR2SMN1; SMN2MEN1 | |
| SCHEMBL23951689 | 0.72 | PGK1 (0.40) | — | |
| SCHEMBL19446199 | 0.72 | PTGS2 (0.48) | ALDH1A1NPC1RAB9A | |
| SCHEMBL12121971 | 0.71 | PTGS2 (0.52) | ALDH1A1CNR2MEN1KMT2AMAPT | |
| SCHEMBL19232082 | 0.71 | TUBB4A (0.37) | NPSR1SMN1; SMN2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3R5, PIK3R1, PIK3R3 | ALDH1A1 3781/4885NPSR1 3997/4885CNR2 3666/4885 |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | ALDH1A1 3781/4885NPSR1 3997/4885CNR2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.